RenalytixAI Prices $74.3M US IPO, Private Placement

Jul 17, 2020

|

NEW YORK ─ RenalytixAI on Thursday priced its planned initial public offering of 11 million ordinary shares of its stock, saying it anticipates gross proceeds of about $74.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Use of the LumiraDx SARS-CoV-2 Antigen Test in Pediatric Practice

Performance Evaluation of the LumiraDx SARS-CoV-2 Antigen Test to Aid Diagnosis of Acute COVID-19 at the Point of Care

An Evaluation of the Detection of SARS-CoV-2 Antigen in a Cohort of Symptomatic and Asymptomatic Patients: Report from the Evaluation of SKUP

Agena Bioscience’s SARS-CoV-2 Tests: Providing Resilience Against the Emergence of New Variants

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Mar

29

Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Apr

06

Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Menu

RenalytixAI Prices $74.3M US IPO, Private Placement

To read the full story....

Breaking News

Quest Acquires Mercy's Outreach Lab Business

Bio-Rad Laboratories, Roche Enter Quality Control Partnership

Ortho Clinical Diagnostics Nabs CE Mark for Semi-Quantitative SARS-CoV-2 Antibody Tests

UK Government Introduces Free COVID-19 Workplace Testing Program

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

What's Popular?

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

OraSure Technologies Updates Plan for SARS-CoV-2 Antigen Self-Test

Sponsorships